SEC EDGAR · Insider purchase
AIM: Equels Thomas K reported buying shares
1 reported purchase of non-derivative securities. Code P includes open-market and private purchases; it does not establish motive.
Follow AIM- Became public
- Nov 12, 2026, 8:00 AM EST
- Event / period date
- Nov 10, 2026
- Collected
- Nov 12, 2026, 8:16 AM EST
Why this is connected
This filing identifies AIM ImmunoTech Inc. as the issuer of the security. The company's SEC identifier connects it to AIM.
Reported transactions
Equels Thomas K (CEO & President)
39,000 shares · Common Stock
Nov 10, 2026 · $0.138 per share
Value calculated from the reported shares and prices: $5,382.00.
Code P covers open-market and private purchases. Grants, option exercises, and tax withholding are excluded from purchase results. Read the source footnotes for ownership and pricing details.
Source evidence
Read the source excerpt or record
<?xml version="1.0"?>
<ownershipDocument>
<schemaVersion>X0609</schemaVersion>
<documentType>4</documentType>
<periodOfReport>2026-11-10</periodOfReport>
<notSubjectToSection16>0</notSubjectToSection16>
<issuer>
<issuerCik>0000946644</issuerCik>
<issuerName>AIM ImmunoTech Inc.</issuerName>
<issuerTradingSymbol>AIM</issuerTradingSymbol>
<issuerForeignTradingSymbol></issuerForeignTradingSymbol>
</issuer>
<reportingOwner>
<reportingOwnerId>
<rptOwnerCik>0001450324</rptOwnerCik>
<rptOwnerName>Equels Thomas K</rptOwnerName>
</reportingOwnerId>
<reportingOwnerAddress>
<rptOwnerNonUSAddressFlag>false</rptOwnerNonUSAddressFlag>
<rptOwnerStreet1>2117 SOUTHWEST HIGHWAY 484</rptOwnerStreet1>
<rptOwnerStreet2></rptOwnerStreet2>
<rptOwnerCity>OCALA</rptOwnerCity>
<rptOwnerState>FL</rptOwnerState>
<rptOwnerZipCode>34473</rptOwnerZipCode>
<rptOwnerStateDescription></rptOwnerStateDescription>
</reportingOwnerAddress>
<reportingOwnerRelationship>
<isDirector>1</isDirector>
<isOfficer>1</isOfficer>
<isTenPercentOwner>0</isTenPercentOwner>
<isOther>0</isOther>
<officerTitle>CEO & President</officerTitle>
<otherText></otherText>
</reportingOwnerRelationship>
</reportingOwner>
<aff10b5One>0</aff10b5One>
<nonDerivativeTable>
<nonDerivativeTransaction>
<securityTitle>
<value>Common Stock</value>
</securityTitle>
<transactionDate>
<value>2026-11-10</value>
</transactionDate>
<deemedExecutionDate></deemedExecutionDate>
<transactionCoding>
<transactionFormType>4</transactionFormType>
<transactionCode>P</transactionCode>
<equitySwapInvolved>0</equitySwapInvolved>
</transactionCoding>
<transactionTimeliness></transactionTimeliness>
<transactionAmounts>
<transactionShares>
<value>39000</value>
</transactionShares>
<transactionPricePerShare>
<value>0.138</value>
</transactionPricePerShare>
<transactionAcquiredDisposedCode>
<value>A</value>
</transactionAcquiredDisposedCode>
</transactionAmounts>
<postTransactionAmounts>
<sharesOwnedFollowingTransaction>
<value>293095</value>
</sharesOwnedFollowingTransaction>
</postTransactionAmounts>
<ownershipNature>
<directOrIndirectOwnership>
<value>D</value>
</directOrIndirectOwnership>
</ownershipNature>
</nonDerivativeTransaction>
</nonDerivativeTable>
<ownerSignature>
<signatureName>/s/ Thomas K Equels</signatureName>
<signatureDate>2026-11-12</signatureDate>
</ownerSignature>
</ownershipDocument>Price change after we could observe it
-16.43% AIM
Adjusted closing prices from Nov 13, 2026 to Nov 19, 2026. SPY changed -5.10% over the same dates. The start is the first available close after both publication and collection. This is a price comparison, not an executed trade, investor profit, or a backtested strategy.
Original documents control. Public records can be amended, and company connections may require interpretation. Nothing here is investment advice.